Payment overview · 2025
General Payments
$245.54
13 reported records · 7 companies
Healthcare provider profile · identity verified
Sammy Lerma, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BASTROP, TX · NPI 1871571950
Verified facts
What the public records show
CMS Open Payments records show Sammy Lerma, M.D. received $245.54 in general payments during 2025 across 13 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $80.67 | 32.9% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.58 | 26.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.62 | 15.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.07 | 7.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.84 | 6.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.62 | 5.5% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $13.14 | 5.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.54 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $80.67 | 5 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $65.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $13.14 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 173 |
| Metformin Hcl | Metformin Hcl | 525 | 159 |
| Lisinopril | Lisinopril | 467 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 118 |
| Alprazolam | Alprazolam | 395 | 64 |
| Gabapentin | Gabapentin | 382 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 329 | 62 |
| Omeprazole | Omeprazole | 327 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 287 | 90 |
| Losartan Potassium | Losartan Potassium | 275 | 92 |
| Trazodone Hcl | Trazodone Hcl | 268 | 82 |
| Meloxicam | Meloxicam | 217 | 85 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 56 |
| Azithromycin | Azithromycin | 169 | 134 |
| Furosemide | Furosemide | 160 | 46 |
| Montelukast Sodium | Montelukast Sodium | 160 | 54 |
| Glipizide | Glipizide | 145 | 39 |
| Tramadol Hcl | Tramadol Hcl | 143 | 48 |
| Simvastatin | Simvastatin | 141 | 37 |
| Clonazepam | Clonazepam | 137 | 20 |
| Ozempic | Semaglutide | 136 | 27 |
| Cephalexin | Cephalexin | 133 | 86 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 133 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 36 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 124 | 16 |
| Carvedilol | Carvedilol | 121 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 42 |
| Diazepam | Diazepam | 118 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 24 |
| Potassium Chloride | Potassium Chloride | 110 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 33 |
| Sertraline Hcl | Sertraline Hcl | 101 | 30 |
| Jardiance | Empagliflozin | 100 | 31 |
| Allopurinol | Allopurinol | 99 | 32 |
| Buspirone Hcl | Buspirone Hcl | 98 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 64 |
| Celecoxib | Celecoxib | 95 | 35 |
| Lorazepam | Lorazepam | 93 | 17 |
| Trulicity | Dulaglutide | 90 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 15 |
| Amoxicillin | Amoxicillin | 87 | 63 |
| Pregabalin | Pregabalin | 81 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 28 |
| Donepezil Hcl | Donepezil Hcl | 77 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 21 |
| Prednisone | Prednisone | 65 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 25 |
| Methylprednisolone | Methylprednisolone | 63 | 37 |
| Ibuprofen | Ibuprofen | 62 | 23 |
| Spironolactone | Spironolactone | 62 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 59 | 12 |
| Mupirocin | Mupirocin | 58 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 21 |
| Methocarbamol | Methocarbamol | 57 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 13 |
| Atenolol | Atenolol | 54 | 13 |
| Eliquis | Apixaban | 54 | 12 |
| Farxiga | Dapagliflozin Propanediol | 53 | 17 |
| Memantine Hcl | Memantine Hcl | 53 | 12 |
| Finasteride | Finasteride | 51 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 20 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Eszopiclone | Eszopiclone | 47 | 13 |
| Famotidine | Famotidine | 47 | 16 |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Lovastatin | Lovastatin | 46 | 14 |
| Glimepiride | Glimepiride | 45 | 15 |
| Ondansetron Odt | Ondansetron | 45 | suppressed |
| Temazepam | Temazepam | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 28 |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 12 |
| Baclofen | Baclofen | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 37 | 21 |
| Nystatin | Nystatin | 37 | 23 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Torsemide | Torsemide | 36 | 13 |
| Valsartan | Valsartan | 36 | 12 |
| Mirtazapine | Mirtazapine | 35 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | 12 |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 13 |
| Linzess | Linaclotide | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 22 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 29 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 16 |
| Acyclovir | Acyclovir | 28 | 14 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 24 | 18 |
| Buprenorphine Hcl | Buprenorphine Hcl | 23 | suppressed |
| Glyburide | Glyburide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Naproxen | Naproxen | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 17 |
| Estradiol | Estradiol | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.54 · 13 records | Kowa Pharmaceuticals America, Inc. | Azstarys, CREON, Dexcom G6 Transmitter, LINZESS, PROCLAIM, TRELEGY ELLIPTA, TRINTELLIX, VRAYLAR, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error